Alder BioPharmaceuticals of Bothell priced its initial public offering of stock at $10, below the expected range of $13 to $15.
Alder shares, listed on Nasdaq under the ticker ALDR, closed up 3 cents at $10.03 in their trading debut Thursday.
The offering raised $80 million before expenses for the biotech company, which is testing two drug candidates it developed — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis.
Alder filed its IPO plans in mid-March, when biotech deals were booming. But investor enthusiasm for the sector has cooled, with the Nasdaq biotechnology index down more than 14 percent since March 18.
- Seahawks' Marshawn Lynch announces retirement in his own, unique fashion
- Black Sabbath calls it a night at the Tacoma Dome — for good
- Seahawks' Russell Wilson writes a thank-you letter to Peyton Manning
- With Marshawn Lynch retired, what will Seahawks do with money they save?
- Marshawn Lynch’s retirement announcement wasn’t classy, but it was perfect